KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of clobetasol propionate ophthalmic nanoemulsion for treating intraocular inflammation and pain associated with cataract surgery: two phase 3 multicentre, randomised, placebo-controlled, double-masked clinical studies.

Andrew Schwartz, Kent Wellish, Fiaz Zaman, Kevin Jong, Ehsan Sadri, Joseph Martel, James Peace, Michael Korenfeld

BMJ Open 16(5) e101177

PMID42192627
PMCIDPMC13202101
DOI10.1136/bmjopen-2025-101177
发表日期2026-05-27
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 multi panel km;另有 1 张未列出。
摘要

摘要

OBJECTIVE: To assess the effect of clobetasol propionate ophthalmic nanoemulsion, 0.05% (clobetasol) on ocular inflammation and eye pain associated with cataract surgery. DESIGN: Two independent twin phase 3 multicentre, randomised, parallel-group, double-masked, placebo-controlled clinical studies. SETTING: The CLOSE-1 and the CLOSE-2 trials, respectively, involved 19 and 17 sites in the USA. PARTICIPANTS: Patients who presented inflammation of at least five cells in the anterior chamber on the first day after routine unilateral cataract surgery INTERVENTIONS: Participants were randomised to either clobetasol or placebo four times a day for 14 days. Follow-up visits occurred on days 3, 8, 15 and 29. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary endpoint was the proportion of patients with anterior chamber cell (ACC) grade 0 on day 8. A key secondary efficacy endpoint was the proportion of patients with a Visual Analogue Scale (VAS) pain score of 0 on day 8. Safety was also assessed. RESULTS: 426 patients were randomised: 281 to the clobetasol arm and 145 to the placebo arm. The proportion of patients with ACC of 0 at day 8 was significantly superior with clobetasol (37.8% vs 18.1%; odds ratio [OR] 2.8; p<0.0001). The percentage of patients with a VAS pain score of 0 on day 8 was greater with clobetasol (54.7% vs 36.5%; OR 2.1; p=0.0005). Related treatment-emergent adverse events were reported in 3.9% of patients on clobetasol and 5.5% on placebo. CONCLUSIONS: Clobetasol propionate ophthalmic nanoemulsion 0.05% is an effective and safe therapeutic option for treating inflammation and pain associated with cataract surgery. TRIAL REGISTRATION NUMBERS: CLOSE-1 (NCT04246801) and CLOSE-2 (NCT04249076).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT flow chart. AE, adverse event; CONSORT, Consolidated Standards of Reporting Trials; FAS, full analysis set population.
非 KM Figure
Figure 2Figure 2. Proportion of patients with absence of inflammation on day 8 (FAS). FAS, full analysis set population.
非 KM Figure
Figure 3Figure 3. Proportion of patients showing improvement in signs of inflammation from baseline (FAS non-RM). FAS non-RM, full analysis non-rescue medication set.
非 KM Figure
Figure 4Figure 4. Reduction of ocular pain over time evaluated by VAS (FAS non-RM). FAS non-RM, full analysis non-rescue medication set; VAS, Visual Analogue Scale (no eye pain=0; worst imaginable eye pain=10).
非 KM Figure
Figure 5Figure 5. Evaluation of eye discomfort, VAS photophobia and best-corrected visual acuity score. VAS, Visual Analogue Scale (no photophobia=0; worst imaginable photophobia=10).
非 KM Figure
Figure 6Figure 6. Intraocular pressure changes from baseline.
非 KM Figure